Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.06.030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026. Verfasst von Kunal Dayma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ocugen India, 5th Floor, AYDIV IT Park, Financial District, Nanakramguda, Hyderabad 500032, Telangana, India. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Genetic Vectors, Genetic Therapy, Gene Transfer Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Gene delivery for neurodegenerative cerebral disorders faces formidable structural and practical challenges. The blood-brain, blood-cerebrospinal fluid, and arachnoid barriers tightly regulate molecular traffic, restrict paracellular diffusion, and actively clear xenobiotics, limiting brain penetration and retention of large molecules and nucleic acid therapeutics. Additional barriers include heterogeneous and diffuse pathology, the need for precise anatomical targeting, vector dose-limiting toxicities, pre-existing and therapy-induced immunity to viral capsids, and procedural risks of neurosurgical or intrathecal administration. These constraints have slowed translation, reflected by the small number of approved central nervous system-directed gene therapies. Against this backdrop, a diverse therapeutic landscape has emerged. In vivo strategies are dominated by adeno-associated virus 9 (AAV9) and AAV2 vectors delivered intravenously, intrathecally (including intracisternal and intracerebroventricular routes), or via image-guided intraparenchymal and intraputaminal infusions, alongside intrathecal antisense oligonucleotides and RNA interference therapeutics. Concurrently, emerging approaches, including engineered AAV capsids, receptor- and transporter-mediated transcytosis, nanoparticle platforms, and focused ultrasound with microbubbles, have demonstrated compelling yet preclinical proof of concept. Future progress will likely depend on convergent advances in machine-learning-guided capsid, more controllable blood-brain barrier modulation, rational route selection tailored to disease topology, and optimized ex vivo and cell-mediated delivery strategies. These innovations could enable a more predictable therapeutic paradigm for cerebral neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ocugen India, 5th Floor, AYDIV IT Park, Financial District, Nanakramguda, Hyderabad 500032, Telangana, India.
- Ocugen, 11 Great Valley Parkway, Malvern, PA 19355, USA. Electronic address: arun@ocugen.com.
Zitieren
APA
Dayma, K., & Upadhyay, A. (2026). Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.06.030
Vancouver
Dayma K, Upadhyay A. Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.06.030
BibTeX
@article{Dayma2026,
author = {Dayma, Kunal and Upadhyay, Arun},
title = {Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.06.030}
}
EUVIMED